Bayer invests 500 million euros for haemophilia A production
written on 12.03.2014
Bayer invests 500 million euros for haemophilia A production
Latest Reports
Spain’s Clinical Trial Landscape
Within the past decade, Spain has developed into a top player in the European clinical trial network. The…
Turkish Pharma: Eyeing Up Exports
Seizing the cost competitiveness of the Turkish market and the government’s nurturing of local manufacturing,…
China Set to Become OxyContin’s Second Largest Market
China is set to become the second largest market for Mundipharma’s OxyContin behind the US. It comes as…